Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC decreased its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 65.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,905 shares of the company’s stock after selling 7,512 shares during the period. Nisa Investment Advisors LLC’s holdings in Myriad Genetics were worth $54,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in MYGN. Nordea Investment Management AB increased its position in Myriad Genetics by 117.0% during the 4th quarter. Nordea Investment Management AB now owns 332,913 shares of the company’s stock worth $4,548,000 after purchasing an additional 179,527 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Myriad Genetics by 8.8% during the 3rd quarter. Franklin Resources Inc. now owns 58,055 shares of the company’s stock worth $1,457,000 after purchasing an additional 4,710 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Myriad Genetics by 1.0% during the third quarter. Geode Capital Management LLC now owns 2,154,035 shares of the company’s stock worth $59,010,000 after buying an additional 21,220 shares in the last quarter. Disciplined Growth Investors Inc. MN raised its position in shares of Myriad Genetics by 21.1% in the third quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock valued at $69,226,000 after buying an additional 440,107 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of Myriad Genetics by 136.9% during the third quarter. Barclays PLC now owns 190,243 shares of the company’s stock valued at $5,210,000 after buying an additional 109,931 shares during the period. 99.02% of the stock is owned by institutional investors and hedge funds.

Myriad Genetics Stock Performance

NASDAQ:MYGN opened at $12.67 on Friday. Myriad Genetics, Inc. has a twelve month low of $12.04 and a twelve month high of $29.30. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -9.75 and a beta of 1.89. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. The firm’s fifty day simple moving average is $14.09 and its 200 day simple moving average is $21.00.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Thursday, November 7th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.08). The company had revenue of $213.30 million during the quarter, compared to analysts’ expectations of $209.82 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same period in the previous year, the company earned ($0.17) EPS. As a group, equities research analysts expect that Myriad Genetics, Inc. will post -0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the stock. Bank of America lowered their target price on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a research note on Friday, December 13th. Morgan Stanley lowered their price objective on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a research report on Monday, November 18th. Stephens reiterated an “equal weight” rating and set a $20.00 target price on shares of Myriad Genetics in a research report on Thursday, January 16th. The Goldman Sachs Group lowered their price target on Myriad Genetics from $29.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday. Finally, StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a report on Thursday, January 9th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Myriad Genetics presently has an average rating of “Hold” and a consensus target price of $22.00.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.